Coming Together to Make a Difference

ARC Industry Advisory Council Charts a Course for Collaboration

The ARC held its biannual Industry Advisory Council meeting in Boston on March 27th, 2017. The day-long meeting was attended by representatives from pharmaceutical and biotech companies developing new treatments for amyloidosis.  This provides a unique opportunity for these companies to unite and develop partnerships of mutual interest.

Part of the modus operandi of the Amyloidosis Research Consortium is to foster cross-company conversations in order to identify areas of resource-wasting replication.  Precompetitive research, educational awareness programs, and developing a streamlined strategy are primary focal points.

Joining us were the following companies that all have drugs in clinical trials for amyloidosis.

  • Alnylam
  • GSK
  • Ionis
  • Janssen
  • Pfizer
  • Prothena
  • Takeda

We were delighted to welcome two new companies to the council for the first time that have products in early stage development.

  • Caelum
  • Intellia

At the meeting the following areas were prioritized:

  • Market access  
  • Epidemiology
  • Awareness
  • Early detection/diagnosis
  • Clinical endpoints and QOL/PROs

 Participating companies will be partnering with the ARC to develop strategies and launch work streams to address them. We look forward to sharing more details on these key areas in the near future.

 

ARC

Amyloidosis Research Consortium, 275 Grove Street, Newton, MA, 02466